DOI QR코드

DOI QR Code

Prognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study

  • Inal, Ali ;
  • Kaplan, M. Ali ;
  • Kucukoner, Mehmet ;
  • Urakci, Zuhat ;
  • Guven, Mehmet ;
  • Nas, Necip ;
  • Yunce, Muharrem ;
  • Isikdogan, Abdurrahman
  • Published : 2012.08.31

Abstract

Background: The majority of patients with gastric cancer in developing countries present with advanced disease. Systemic chemotherapy therefore has limited impact on overall survival. Patients eligible for chemotherapy should be selected carefully. The aim of this study was to analyze prognostic factors for survival in advanced gastric cancer patients undergoing first-line palliative chemotherapy. Methods: We retrospectively reviewed 107 locally advanced or metastatic gastric cancer patients who were treated with docetaxel and cisplatin plus fluorouracil (DCF) as first-line treatment between June 2007 and August 2011. Twenty-eight potential prognostic variables were chosen for univariate and multivariate analyses. Results: Among the 28 variables of univariate analysis, nine variables were identified to have prognostic significance: performance status, histology, location of primary tumor, lung metastasis, peritoneum metastasis, ascites, hemoglobin, albumin, weight loss and bone metastasis. Multivariate analysis by Cox proportional hazard model, including nine prognostic significance factors evident in univariate analysis, revealed weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level to be independent variables. Conclusion: Performance status, weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level were identified as important prognostic factors in advanced gastric cancer patients. These findings may facilitate pretreatment prediction of survival and can be used for selecting patients for treatment.

Keywords

Gastric cancer;first-line chemotherapy;prognostic factors

References

  1. Andreyev HJ, Norman AR, Oates J, Cunningham D (1998). Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer, 34, 503-9. https://doi.org/10.1016/S0959-8049(97)10090-9
  2. Chau I, Norman AR, Cunningham D, et al (2004). Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol, 15, 2395-403.
  3. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90 https://doi.org/10.3322/caac.20107
  4. Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8, 163-8. https://doi.org/10.1023/A:1008243606668
  5. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH (2005). Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol, 23, 175-83. https://doi.org/10.1200/JCO.2005.04.177
  6. Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. JCO, 24, 2137-50. https://doi.org/10.1200/JCO.2005.05.2308
  7. Kanagavel D, Pokataev IA, Fedyanin MY, et al (2010). A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol, 21, 1779-85. https://doi.org/10.1093/annonc/mdq032
  8. Kim JG, Ryoo BY, Park YH, et al (2008). Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol, 61, 301-7
  9. Krishnan S, Rana V, Janjan NA, et al (2006). Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 107, 2589-96. https://doi.org/10.1002/cncr.22328
  10. Lee J, Lim T, Uhm JE, et al (2007). Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol, 18, 886-91. https://doi.org/10.1093/annonc/mdl501
  11. Maroufizadeh S, Maroufizadeh S, Hajizadeh E, Baghestani AR, Fatemi SR (2011). Multivariate analysis of prognostic factors in gastric cancer patients using additive hazards regression models. Asian Pac J Cancer Prev, 12, 1697-702.
  12. Mitry E, Douillard JY, van Cutsem E, et al (2004). Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial. Ann Oncol, 15, 1013-7. https://doi.org/10.1093/annonc/mdh267
  13. Murad AM, Santiago FF, Petroianu A, et al (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer, 72, 37-41. https://doi.org/10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
  14. Park SH, Lee J, Lee SH, et al (2006). Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based firstline chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol, 57, 91-6. https://doi.org/10.1007/s00280-005-0027-2
  15. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995). Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 71, 587-91. https://doi.org/10.1038/bjc.1995.114
  16. Roshanaei G, Ghannad MS, Jafarabadi MA, Faradmal J, Sadighi S (2011). Prognostic impact of risk factors in patients with gastric cancer in Iran. Asian Pac J Cancer Prev, 12, 3005-8.
  17. Roth AD, Fazio N, Stupp R, et al (2006). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol, 25, 3217-23.
  18. Roshanaei G, Ghannad MS, Jafarabadi MA, Faradmal J, Sadighi S (2011). Prognostic impact of risk factors in patients with gastric cancer in Iran. Asian Pac J Cancer Prev, 12, 3005-8.
  19. Sadeghi B, Arvieux C, Glehen O, et al (2000). Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer, 88, 358-63. https://doi.org/10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O
  20. Sougioultzis S, Syrios J, Xynos ID, et al (2010). A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol, 21, 1779-85. https://doi.org/10.1093/annonc/mdq032
  21. Tsujitani S, Oka S, Suzuki K, et al (2001). Prognostic factors in patients with advanced gastric cancer treated by noncurative resection: a multivariate analysis. Hepatogastroenterology, 48, 1504-8.
  22. Van Cutsem E, Moiseyenko VM, Tjulandin SA, et al (2006). V325 Study Group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol, 24, 4991-7. https://doi.org/10.1200/JCO.2006.06.8429
  23. Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol, 24, 2903-9 https://doi.org/10.1200/JCO.2005.05.0245
  24. Yoshida M, Ohtsu A, Boku N, et al (2004). Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol, 34, 654-9. https://doi.org/10.1093/jjco/hyh120

Cited by

  1. Lymphangiogenic and Angiogenic Microvessel Density in Chinese Patients with Gastric Carcinoma: Correlation with Clinicopathologic Parameters and Prognosis vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4549
  2. Treatment of patients with advanced gastric cancer: experience from an Indian tertiary cancer center vol.31, pp.10, 2014, https://doi.org/10.1007/s12032-014-0138-x
  3. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer vol.73, pp.1, 2014, https://doi.org/10.1007/s00280-013-2334-3
  4. Is there any Potential Clinical Impact of Serum Phosphorus and Magnesium in Patients with Lung Cancer at First Diagnosis? A Multi-institutional Study vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.77
  5. Clinical Characteristics Associated with Long-term Survival in Metastatic Gastric Cancer after Systemic Chemotherapy vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5433
  6. Efficacy and Tolerability of Weekly Docetaxel, Cisplatin, and 5-Fluorouracil for Locally Advanced or Metastatic Gastric Cancer Patients with ECOG Performance Scores of 1 and 2 vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.985
  7. Beneficial Effect of Educational and Nutritional Intervention on the Nutritional Status and Compliance of Gastric Cancer Patients Undergoing Chemotherapy: A Randomized Trial vol.69, pp.5, 2017, https://doi.org/10.1080/01635581.2017.1321131